Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # SciBase gy ## Sitemaps - [XML Sitemap](https://scibase.com/sitemap.xml): Contains all public & indexable URLs for this website. ## News - [SciBase Holding AB (publ) proposes a preferential rights issue of SEK 85 million, secured to SEK 75 million](https://scibase.com/uk/scibase-holding-ab-publ-proposes-a-preferential-rights-issue-of-sek-85-million-secured-to-sek-75-million/) - Summary The board of directors of SciBase Holding AB (publ) ("SciBase" or "The Company") has decided to propose a new share issue of approximately SEK 85 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price in the Rights Issue is set to SEK 9.00. The Rights Issue is subject - [NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN SCIBASE HOLDING AB (PUBL)](https://scibase.com/uk/notice-to-attend-extraordinary-general-meeting-in-scibase-holding-ab-publ/) - The shareholders of SciBase (publ), reg.no 556773-4768 (the "Company") are hereby summoned to an extraordinary general meeting on Tuesday 7 September 2021. - [SciBase letter from the CEO number 4: Updated strategy and securing our long-term capital needs](https://scibase.com/uk/scibase-letter-from-the-ceo-number-4-updated-strategy-and-securing-our-long-term-capital-needs/) - This summer’s great news, the FDA approval of Nevisense, was an important milestone in the history of the Company. We are very pleased and proud of our achievement, and following this we have together with the board further developed our strategy. The updated strategy includes new clinical applications built on our existing Nevisense platform, and - [SciBase receives order of up to 1 million SEK within a new customer segment in Italy](https://scibase.com/scibase-receives-order-of-up-to-1-million-sek-within-a-new-customer-segment-in-italy/) - SciBase has signed a new distribution agreement in Italy with International Health and Fitness Organisation AB (IHFO), a Swedish distributor active in Italy, within a completely new customer segment. As part of the signing, SciBase received an initial order of approx. 0.5 million SEK consisting of Nevisense systems and single use electrodes for delivery during the fourth quarter 2017. In addition IHFO has an option to place a follow-up order of more Nevisense and electrodes of an additional 0.5 million SEK to be delivered during 2018. The Nevisense systems ordered by IHFO will be placed at a number of pharmacies and non-specialist clinics in Italy that will perform melanoma screening tests. - [SciBase receives first commercial order in the US from private clinic in New York](https://scibase.com/scibase-receives-first-commercial-order-in-the-us-from-private-clinic-in-new-york/) - SciBase has received the first commercial order in the US - from a private clinic with a focus on self-pay patients in Manhattan, New York. The order, consisting of a Nevisense system and single-use electrodes, is strategically important as it can be seen as an early sign that our launch strategy is the right approach. SciBase’s strategy focuses initially on marketing Nevisense to private clinics with self-pay patients in the New York Metropolitan Area. - [Goldenberg Dermatology first in the US to offer SciBase's Nevisense screening for early detection of melanoma](https://scibase.com/goldenberg-dermatology-first-in-the-us-to-offer-scibases-nevisense-screening-for-early-detection-of-melanoma/) - November 9th SciBase announced that the Company had received the first order in the US from Goldenberg Dermatology, a premier New York City dermatology practice of Dr. Gary Goldenberg and Dr. Kristina Goldenberg. The order, consisting of a Nevisense system and single-use electrodes, means that Drs. Goldenberg will be the first dermatologists in the US to be able to offer the Nevisense test for early detection of melanoma and atypical moles (nevi). Earlier this fall, at the Fall Clinical Dermatology Conference SciBase was mentioned as one of the ten most important new technologies within skin cancer detection. - [Bulletin from extra general meeting of SciBase Holding AB (publ) on 15 November 2017](https://scibase.com/uk/bulletin-from-extra-general-meeting-of-scibase-holding-ab-publ-on-15-november-2017/) - At the extraordinary general meeting of SciBase Holding AB (publ) on 15 November 2017 in Stockholm the shareholders adopted the below resolutions. - [Publication of prospectus in connection with SciBase's preferential rights issue](https://scibase.com/publication-of-prospectus-in-connection-with-scibases-preferential-rights-issue/) - The board of directors of SciBase Holding AB (publ) (”SciBase” or ”the Company”) has today published a prospectus in connection with the new share issue with preferential rights for the Company’s shareholders of approximately SEK 85 million, which was announced on 26 October 2017. - [SciBase announces the prospectus and terms and conditions for preferential rights issue](https://scibase.com/scibase-announces-the-prospectus-and-terms-and-conditions-for-preferential-rights-issue/) - Read about the prospectus and terms and conditions - [CEO Simon Grant presents at Avanza börsdagen on Nov 23rd](https://scibase.com/uk/ceo-simon-grant-presents-at-avanza-borsdagen-on-nov-23rd/) - CEO Simon Grant presents at Avanza börsdagen on Nov 23rd, 2017, 11.30. The presentation will be live-streamed https://tv.streamfabriken.com/2017-11-23-scibase - [CEO Simon Grant presents at Redeye Life Science days on Nov 24th](https://scibase.com/ceo-simon-grant-presents-at-redeye-life-science-days-on-nov-24th/) - CEO Simon Grant presents at Redeye Life Science days on Nov 24th, 15.25 https://www.redeye.se/live/life-science-seminar-2017 - [SciBase publishes prospectus in connection with SciBase’s preferential rights issue](https://scibase.com/scibase-publishes-prospectus-in-connection-with-scibases-preferential-rights-issue/) - SciBase publishes prospectus in connection with SciBase’s preferential rights issue, Nov 20, 2017 Welcome to subscribe at SciBase rights offering Read more - [SciBase closes first DermoScan integration sale in Germany](https://scibase.com/scibase-closes-first-dermoscan-integration-sale-in-germany/) - SciBase has received the first order from a customer as a result of their co-operation with the German medical technology company DermoScan. The order comes from a clinic in Munich that is a user of a DermoScan digital dermoscopy system and who has now chosen to add Nevisense to its diagnostic process. - [SciBase announces outcome of the preferential rights issue](https://scibase.com/uk/scibase-announces-outcome-of-the-preferential-rights-issue/) - Outcome of the Offering SciBase Holding AB (publ) (”SciBase” or the ”Company”) today announces that the secured new share issue with preferential rights for existing shareholders (the ”Offering”) has been completed and will provide the Company with approximately SEK 75 million before deduction of transaction costs. A total of approximately SEK 39.2 million, corresponding to 46.1 percent of the full Offering was subscribed for. Approximately SEK 36.6 million, corresponding to 43.0 percent of the Offering, was subscribed for by way of subscription rights and approximately SEK 2.5 million, corresponding to 3.0 percent of the Offering, was subscribed for without exercise of subscription rights. The remaining part of the secured part of the Offering of SEK 75 million, corresponding to SEK 35.8 million or 42.0 percent of the total Offering amount of SEK 85 million, was allocated to guarantors. - [SciBase Letter from the CEO no 5: Launch of updated Strategy](https://scibase.com/uk/scibase-letter-from-the-ceo-no-5-launch-of-updated-strategy/) - The last few months have been very intense. We have launched our updated growth strategy focusing on the US and German markets, as well as working hard on our new share issue. The share issue, which was completed about a week ago, has provided the Company with approximately MSEK 65 after transaction costs, providing leeway - [Notice of the Annual General Meeting in SciBase Holding AB (publ)](https://scibase.com/uk/notice-of-the-annual-general-meeting-in-scibase-holding-ab-publ/) - The shareholders of SciBase Holding AB (publ), reg. no. 556773-4768, (hereinafter the "Company") are hereby invited to the Annual General Meeting to be held on Wednesday June 17, 2020 at 4.00 p.m. CET at Setterwalls Advokatbyrå's offices with address at Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes prior to the opening of the meeting. - [SciBase publishes the Annual report for 2017](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2017/) - SciBase hereby announces that the Annual report for 2017 is available at the Company’s website www.scibase.com. - [Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2018](https://scibase.com/uk/bulletin-from-annual-general-meeting-of-scibase-holding-ab-publ-on-16-may-2018/) - At the annual general meeting of SciBase Holding AB (publ) on 16 May 2018 in Stockholm the shareholders adopted the below resolutions. - [Improved accuracy and usability for SciBase Nevisense can create a larger market](https://scibase.com/improved-accuracy-and-usability-for-scibase-nevisense-can-create-a-larger-market/) - SciBase announced today that they have achieved positive and promising results in their validation testing of an improved measurement method and algorithm for melanoma detection with their product Nevisense. The changes include a streamlining of the measurement method so that is easier to learn and use. The aim of the change is a dramatic improvement - [SciBase releases major improvements to Nevisense](https://scibase.com/uk/scibase-releases-major-improvements-to-nevisense/) - The previously announced breakthrough update to Nevisense, SciBase device for the early detection of melanoma, has now been released. - [New US Study: Nevisense shows significant positive impact on clinical decision making](https://scibase.com/new-us-study-nevisense-shows-significant-positive-impact-on-clinical-decision-making/) - New data has been presented in a US publication showing that by including the Nevisense result in clinical decision-making, physicians significantly improved their accuracy in identifying malignant melanoma. The article, titled “Assessment of Clinician Accuracy for Diagnosing Melanoma Based on Electrical Impedance Spectroscopy Score Plus Morphology Versus Lesion Morphology Alone” by Dr Ryan M. Svoboda - [The following people have been appointed as members of SciBase Holding's election committee for the Annual General Meeting in 2019:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-election-committee-for-the-annual-general-meeting-in-2019/) - Andreas Pennervall chairman (representing SEB Venture Capital, Filip Petersson (SEB pensionsstiftelse), Christer Jönsson (Fouriertransform), Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of SciBase Holding on May 16, 2018. - [Clinical Guideline for Nevisense published in Germany](https://scibase.com/clinical-guideline-for-nevisense-published-in-germany/) - A new clinical guideline supporting the use of Nevisense in the evaluation of lesions with suspicion of melanoma has been published in the German magazine “Der Deutsche Dermatologe”. The guideline is written by Prof Julia Welzel, Augsburg and Prof Uwe Reinhold, Bonn and has the backing and support of Onkoderm, a German dermatology society for - [SciBase announces skin barrier testing collaboration with leading Swiss research center](https://scibase.com/uk/scibase-announces-skin-barrier-testing-collaboration-with-leading-swiss-research-center/) - SciBase and Swiss Institute of Allergy and Asthma Research, Davos Switzerland (SIAF-SFI) announced today the signing of a formal collaboration agreement within the area of barrier function testing using Electrical Impedance Spectroscopy (EIS). In addition the partners have jointly filed a patent application covering the use of electrical impedance testing for the evaluation of epithelial - [New study opens up new applications for SciBase's product Nevisense](https://scibase.com/uk/new-study-opens-up-new-applications-for-scibases-product-nevisense/) - The Swiss Institute of Allergy and Asthma Research (SIAF) and SciBase announce today the publication of a breakthrough animal study within the area of skin barrier assessment. The paper, which is entitled ‘Direct assessment of skin epithelial barrier by electrical impedance spectroscopy’, was published online in the journal Allergy, European Journal of Allergy and Clinical - [Letter from the CEO, SciBase April 2019](https://scibase.com/uk/letter-from-the-ceo-scibase-april-2019/) - Dear SciBase shareholders, - [Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2019](https://scibase.com/uk/bulletin-from-annual-general-meeting-of-scibase-holding-ab-publ-on-16-may-2019/) - At the annual general meeting of SciBase Holding AB (publ) on 16 May 2019 in Stockholm the shareholders adopted the below resolutions. - [SciBase announces first sale within the new Skin Barrier application](https://scibase.com/uk/scibase-announces-first-sale-within-the-new-skin-barrier-application/) - SciBase today announces the first sale and shipment of SciBase products for the evaluation of skin barrier function. The first shipment is to a prestigious hospital in Japan for research into skin barrier function in infants. - [SciBase publishes the Annual report for 2018](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2018/) - SciBase hereby announces that the Annual report for 2018 is available at the Company’s website www.scibase.com. - [SciBase receives breakthrough order from large US dermatology group](https://scibase.com/scibase-receives-breakthrough-order-from-large-us-dermatology-group/) - SciBase today announces the first multi system order from a large dermatology practice group. Advanced Dermatology, P.C. is a group of over 40 dermatology practices in the New York tri-state area. - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2020:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2020/) - Frederick Johansson (representing SEB Venture Capital, Filip Petersson (SEB pensionsstiftelse), Christer Jönsson (Fouriertransform), Tord Lendau (Chairman of the Board). The appointments have been made in acco... - [SciBase announces order of Nevisense from Mount Sinai Hospital's New Melanoma Clinic](https://scibase.com/scibase-announces-order-of-nevisense-from-mount-sinai-hospitals-new-melanoma-clinic/) - STOCKHOLM, Sweden, - November 12, 2019 - SciBase a leading developer of electrical impedance spectroscopy systems in dermatology, announced today that The Kimberly and Eric J. Waldman Department of Dermatology at Mou... - [Interim report](https://scibase.com/uk/interim-report/) - January 1 -March 31, 2024 - [SciBase Holding AB announces changes in the Board](https://scibase.com/uk/scibase-holding-ab-announces-changes-in-the-board/) - Thomas Eklund, member of the board, has announced that he resigns effective today from the Board of SciBase Holding AB at his own request. Thomas has decided to resign from SciBase and other Board positions due to l... - [SciBase to present this week at Swiss-Nordic Bio 2020](https://scibase.com/uk/scibase-to-present-this-week-at-swiss-nordic-bio-2020/) - SciBase, a leading manufacturer of solutions within skin diagnostics announced today that they will present at the Swiss-Nordic Bio 2020 conference in Zurich this week. "I look forward to presenting an update... - [The board of directors of SciBase has resolved on a fully guaranteed rights issue of units consisting of shares and warrants, subject to the approval of a general meeting](https://scibase.com/uk/the-board-of-directors-of-scibase-has-resolved-on-a-fully-guaranteed-rights-issue-of-units-consisting-of-shares-and-warrants-subject-to-the-approval-of-a-general-meeting/) - NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. - [Notice of an Extraordinary General Meeting of SciBase Holding AB (publ)](https://scibase.com/uk/notice-of-an-extraordinary-general-meeting-of-scibase-holding-ab-publ/) - The shareholders of SciBase Holding AB (publ), reg. no. 556773-4768, are hereby invited to an extraordinary general meeting on Wednesday, April 29, 2020 at 10.00 a.m. CET at Setterwalls Advokatbyrå's premises at Sturegatan 10 in Stockholm, Sweden. Registration for the meeting commences 30 minutes prior to the opening of the meeting. - [Changes in SciBase's financial calendar for 2020](https://scibase.com/uk/changes-in-scibases-financial-calendar-for-2020/) - SciBase Holding AB ("SciBase" or the "Company") has updated the Company's financial calendar for 2020. Due to the preparation of the rights issue announced earlier today, the Company has r... - [SciBase publishes the Annual report for 2019](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2019/) - SciBase hereby announces that the Annual report for 2019 is available at the Company's website www.scibase.com. - [Comments on Covid-19](https://scibase.com/uk/comments-on-covid-19/) - The consequences of the Covid19 outbreak have started to affect SciBase from mid-March, and there is a high risk that these could lead to a significant financial impact on the Group. However, the effects are very difficult to predict, and the situation is constantly changing. First and foremost, we at SciBase are working to ensure - [Extraordinary General Meeting April 29, 2020 : Special Procedure Due To The Spread Of Coronavirus](https://scibase.com/extraordinary-general-meeting-april-29-2020-special-procedure-due-to-the-spread-of-coronavirus/) - SPECIAL PROCEDURE DUE TO THE SPREAD OF CORONAVIRUS In light of the spread of the coronavirus, the board of directors has decided to implement certain precautionary measures for the extraordinary general meeting on 29 April 2020 in order to ascertain the well-being of the company’s shareholders’ as well as the opportunity for them to exercise - [Summary of extraordinary general meeting in SciBase Holding AB (publ)](https://scibase.com/uk/summary-of-extraordinary-general-meeting-in-scibase-holding-ab-publ/) - Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved, in accordance with the proposals presented in the not... - [SciBase AI based solutions seen as an interesting use case](https://scibase.com/uk/scibase-ai-based-solutions-covered-in-a-blog/) - SciBase AI based developments and solutions are seen as being on the forefront, and are covered in the AI Company Peltarion's Blog: "Can a pen from the future change the lives for millions of children with eczema, asthma and allergies?" Please follow the link to read the story: https://peltarion.com/blog/applied-ai/scibase - [SciBase receives FDA approval for Nevisense 3.0](https://scibase.com/uk/scibase-receives-fda-approval-for-nevisense-3-0/) - SciBase (SCIB) Stockholm, Sweden - announced today that it has received approval from the US Food and Drug Administration (FDA) for Nevisense 3.0, the third generation of their Nevisense system for early melanoma det... - [SciBase and Advanced Dermatology and Cosmetic Surgery group partner to advance skin cancer detection in US' largest dermatology network](https://scibase.com/scibase-and-advanced-dermatology-and-cosmetic-surgery-group-partner-to-advance-skin-cancer-detection-in-us-largest-dermatology-network/) - Stockholm, Sweden - SciBase (SCIB) announced today, on "Melanoma Monday", that they have entered into a collaboration agreement with Advanced Dermatology and Cosmetic Surgery ("ADCS") - the premie... - [SciBase publishes prospectus in connection with a fully guaranteed rights issue of units consisting of shares and warrants](https://scibase.com/scibase-publishes-prospectus-in-connection-with-a-fully-guaranteed-rights-issue-of-units-consisting-of-shares-and-warrants/) - The board of directors of SciBase Holding AB (publ) ("Scibase" or the "Company") has prepared a prospectus in connection with the issue of units consisting of shares and warrants with preferential rights for the Company's shareholders of up to approximately SEK 24.9 million (the "Rights Issue") announced by the Company through press release on 26 March 2020. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company's website. - [Letter from the CEO, May 2020](https://scibase.com/uk/letter-from-the-ceo-may-2020/) - I trust and hope that you are all well in these trying times. I'm very thankful that the team at SciBase has come through this unscathed so far. At the same time the landscape of our family life and our work life has undergone real changes in the recent months and I expect some of - [SciBase covered by BioStock](https://scibase.com/uk/scibase-covered-by-biostock/) - SciBase market potential and the opportunity to invest in the company is covered in an article by BioStock (in Swedish) See: https://www.biostock.se/2020/05/scibase-forbattrar-cancerupptackter/ - [CEO Simon Grant presents at Redeye Investor Forum Online](https://scibase.com/ceo-simon-grant-presents-at-redeye-investor-forum-online/) - SciBase clinical and business opportunities were presented by CEO Simon Grant at the Redeye Investor Forum Online May 12th. Please see the presentation through the following link: Redeye presentation - [SciBase's rights issue heavily oversubscribed](https://scibase.com/uk/scibases-rights-issue-heavily-oversubscribed/) - NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. - [DermaLive webinar](https://scibase.com/dermalive-webinar/) - Listen to the DermaLive webinar (in German), presenting "INNOVATIVE DIAGNOSTIC TOOLS IN DERMATOLOGY" (and receive CME credits). On line on June 10th at 6 PM (CET), or afterwards as a video-on-demand. Presenters are Prof Julia Welzel, Dr Martina Ulrich, Prof Uwe Reinhold and Prof Cezmi Akdis, and morderator is Prof Thomas Dirschka. Access through Streamed-up.com - [SciBase submits reimbursement application and targets 2021 for first reimbursement coverage in the US](https://scibase.com/scibase-submits-reimbursement-application-and-targets-2021-for-first-reimbursement-coverage-in-the-us/) - Stockholm, June 15th, 2020 - SciBase, a global healthcare company with a platform technology enabling innovative products for skin disorders such as skin cancer and atopic dermatitis, today announces that the company has submitted a reimbursement code application for its melanoma application to the Centers for Medicare & Medicaid Services (CMS) in the US. - [Annual general meeting has been held in SciBase Holding AB (publ)](https://scibase.com/uk/annual-general-meeting-has-been-held-in-scibase-holding-ab-publ/) - Today, the annual general meeting of 2024 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the resolutions passed at the annual general meeting, which included the election of Jesper Høiland and Robert Molander as new members of the board of directors and the election of Jesper Høiland as new chairman of the board of directors. - [SciBase installs Nevisense Systems at Advanced Dermatology and Cosmetic Surgery Group in Florida](https://scibase.com/scibase-installs-nevisense-systems-at-advanced-dermatology-and-cosmetic-surgery-group-in-florida/) - The nation's premier dermatology group begins rollout of Nevisense technology to examine patients with irregular moles suspicious of melanoma - [SciBase announces a Management team change](https://scibase.com/uk/scibase-announces-a-management-team-change/) - SciBase's head of product development, David Melin, has resigned from his position and has accepted a role at another company. The company is reviewing options for the role going forward. "I would like to... - [Nevisense selected for `SpotCheck' remote melanoma detection evaluation study by The Ronald O. Perelman Department of Dermatology at NYU Langone Health](https://scibase.com/nevisense-selected-for-spotcheck-remote-melanoma-detection-evaluation-study-by-the-ronald-o-perelman-department-of-dermatology-at-nyu-langone-health/) - Stockholm, Sweden and New York, USA - August 18, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that Nevi... - [SciBase's Nevisense product included in infant study at Mount Sinai Hospital](https://scibase.com/scibases-nevisense-product-included-in-infant-study-at-mount-sinai-hospital/) - Stockholm, Sweden and New York, USA - August 26, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they will participate in a clinical study to run parallel to the ACTIVATE study (sponsored by the Immune Tolerance Network and the NIAID/NIH), which is being conducted by the Department of Pediatric Allergy at Mount Sinai Hospital in New York. - [New Clinical Studies show Improved Melanoma Detection by US clinicians with Nevisense](https://scibase.com/new-clinical-studies-show-improved-melanoma-detection-by-us-clinicians-with-nevisense/) - STOCKHOLM, SWEDEN, - September 16, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that both the Journal of the American Academy of Dermatology (JAAD) and SKIN, The Journal of Cutaneous Medicine (SKIN), have published studies assessing the clinical impact of Nevisense. The studies compared the results of US clinicians evaluating atypical pigmented skin lesions (atypical moles) using visual evaluation only compared to visual evaluation and the Nevisense result combined. - [Conversion of Warrants](https://scibase.com/uk/conversion-of-warrants/) - Information about conversion of warrants (TO1) is available in the investors pages (in Swedish). Please follow the link: http://investors.scibase.se/sv/information-avseende-omvandling-av-teckningsoptioner-to1 - [Letter from the CEO](https://scibase.com/uk/letter-from-the-ceo/) - In my initial 100 days as CEO, I have been creating a roadmap for SciBase's rapid transition into a robust commercial company. I am impressed by the work that has been done so far, but I am at the same time confident that with a more focused approach, we can significantly enhance value for our shareholders, the healthcare sector, and patients. - [Exercise price for warrants of series TO1 in SciBase Holding AB determined and the subscription period commence on 5 October 2020](https://scibase.com/exercise-price-for-warrants-of-series-to1-in-scibase-holding-ab-determined-and-the-subscription-period-commence-on-5-october-2020/) - NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. - [SciBase Holding AB announces the outcome of the exercise of warrants of series TO1](https://scibase.com/uk/scibase-holding-ab-announces-the-outcome-of-the-exercise-of-warrants-of-series-to1/) - SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1. - [SciBase Holding AB announces the outcome of the exercise of warrants of series TO1](https://scibase.com/uk/scibase-holding-ab-announces-the-outcome-of-the-exercise-of-warrants-of-series-to1-2/) - SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1. - [SciBase Holding AB announces the outcome of the exercise of warrants of series TO1](https://scibase.com/uk/scibase-holding-ab-announces-the-outcome-of-the-exercise-of-warrants-of-series-to1-3/) - SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1. - [SciBase releases next generation platform, Nevisense Go.](https://scibase.com/uk/scibase-releases-next-generation-platform-nevisense-go/) - STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go. - [SciBase releases next generation platform, Nevisense Go.](https://scibase.com/uk/scibase-releases-next-generation-platform-nevisense-go-2/) - STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go. - [SciBase releases next generation platform, Nevisense Go.](https://scibase.com/uk/scibase-releases-next-generation-platform-nevisense-go-3/) - STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go. - [Positive step for US reimbursement of Nevisense](https://scibase.com/positive-step-for-us-reimbursement-of-nevisense/) - STOCKHOLM, SWEDEN, - November 2, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT®(CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test. - [Positive step for US reimbursement of Nevisense](https://scibase.com/positive-step-for-us-reimbursement-of-nevisense-2/) - STOCKHOLM, SWEDEN, - November 2, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT®(CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test. - [Positive step for US reimbursement of Nevisense](https://scibase.com/positive-step-for-us-reimbursement-of-nevisense-3/) - STOCKHOLM, SWEDEN, - November 2, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT®(CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test. - [SciBase announces changes to the Management team](https://scibase.com/uk/scibase-announces-changes-to-the-management-team/) - Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team. "Our manufacturing of single use electrodes is of strategic importance to the Company an... - [SciBase announces changes to the Management team](https://scibase.com/uk/scibase-announces-changes-to-the-management-team-2/) - Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team. "Our manufacturing of single use electrodes is of strategic importance to the Company an... - [SciBase announces changes to the Management team](https://scibase.com/uk/scibase-announces-changes-to-the-management-team-3/) - Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team. "Our manufacturing of single use electrodes is of strategic importance to the Company and one of our more important projects going forward is to streamline the manufacturing process and increase the production capacity. Therefore, it is only natural that Linn, who started at SciBase in August, now becomes a member of the management team. With Linn on the team we get important strategic competence into the management team", says Simon Grant CEO SciBase. For more information please contact:Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: simon.grant@scibase.com Certified Asdvisor:Avanza Tel: +46 8 409 421 20 Email: ca@avanza.se The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase's news distributor Cision upon publication of this press release. About SciBase and NevisenseSciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com. - [Interim report](https://scibase.com/uk/interim-report-2/) - January 1 - September 30, 2020 - [Interim report](https://scibase.com/uk/interim-report-3/) - January 1 – March 31, 2021 - [New Study published validating further Nevisense indication, Non-melanoma Skin Cancer](https://scibase.com/uk/new-study-published-validating-further-nevisense-indication-non-melanoma-skin-cancer/) - New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan... - [New Study published validating further Nevisense indication, Non-melanoma Skin Cancer](https://scibase.com/uk/new-study-published-validating-further-nevisense-indication-non-melanoma-skin-cancer-2/) - New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan... - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2021:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2021-2/) - Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles ... - [New Study published validating further Nevisense indication, Non-melanoma Skin Cancer](https://scibase.com/uk/new-study-published-validating-further-nevisense-indication-non-melanoma-skin-cancer-3/) - New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan to broaden the areas of use of Nevisense A new study supporting the use of Nevisense for the evaluation of lesions where there is a suspicion of non-melanoma skin cancer (NMSC) has been published in "Acta Dermato-Venereologica". The article is authored by Dr Esra Sarac, Prof Claus Garbe and others from Eberhard Karls University in Tübingen, Germany. NMSC represents a new indication that complements the current melanoma indication and greatly expands the utility of Nevisense for clinicians working with skin cancer. "This study shows that Nevisense is a valuable tool not only for melanoma but also for other types of skin cancer such as basal cell carcinoma and squamous cell carcinoma. These non-melanoma skin cancers are 10-15 times more prevalent than melanoma, and so the new indication will be more useful to more clinicians and patients. The publication is another milestone in our strategy to broaden the clinical applications and markets for Nevisense. Nevisense with NMSC is now in the final stages of regulatory approval in the EU as part of the new Medical Device Regulation approval route. Once approved, we expect the added indication will make Nevisense more attractive for new customers and expand the level of usage of existing customers", says Simon Grant, CEO of SciBase. The article is titled "Diagnostic Accuracy of Electrical Impedance Spectroscopy in Nonmelanoma Skin Cancer" and evaluates the accuracy of Nevisense and Electrical Impedance spectroscopy (EIS) on suspected non-melanoma skin cancers. The article shows that Nevisense is well suited for use with NMSC and states that "EIS has good discriminative power to distinguish NMSC from benign cutaneous lesions". The conclusion in the article states: "The results of this study suggest that electrical impedance spectroscopy measurements can improve diagnostic performance with a high sensitivity in detection of non-melanoma skin cancer." The article is now available in online form at the Acta Dermato-Venereologica's website (https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3689) and will be distributed in print in the next issue of the publication. For more information please contact:Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: simon.grant@scibase.com Certified Advisor:Avanza Tel: +46 8 409 421 20 Email: ca@avanza.se About SciBase and NevisenseSciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com. - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2021:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2021-3/) - Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2020. Note, however, that the appointment took into account changes in ownership that took place during the end of 2020. The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2021 in Stockholm. Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting. Stockholm, February 2, 2021 SciBase Holding AB (publ) For more information, please contact:Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67 Michael Colérus, CFO, phone +46 70 341 34 72 Certified Advisor (CA): Avanza Tel: +46 8 409 421 20 Email: ca@avanza.se About SciBase and NevisenseSciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com. - [Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application](https://scibase.com/further-study-supports-use-of-nevisense-within-new-non-melanoma-skin-cancer-application/) - A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense - [Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application](https://scibase.com/further-study-supports-use-of-nevisense-within-new-non-melanoma-skin-cancer-application-2/) - A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense - [Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application](https://scibase.com/further-study-supports-use-of-nevisense-within-new-non-melanoma-skin-cancer-application-3/) - A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense - [SciBase's US Partner study shows COVID-19 delaying skin cancer diagnosis](https://scibase.com/scibases-us-partner-study-shows-covid-19-delaying-skin-cancer-diagnosis/) - A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases rem... - [SciBase's US Partner study shows COVID-19 delaying skin cancer diagnosis](https://scibase.com/scibases-us-partner-study-shows-covid-19-delaying-skin-cancer-diagnosis-2/) - A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases rem... - [SciBase publishes the Annual report for 2020](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2020/) - SciBase hereby announces that the Annual report for 2020 is available at the Company's website www.scibase.com. - [New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis](https://scibase.com/new-clinical-study-shows-nevisense-potential-for-assessment-of-skin-barrier-and-atopic-dermatitis/) - STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase's strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms. - [SciBase MDR certification delayed two weeks](https://scibase.com/scibase-mdr-certification-delayed-two-weeks/) - STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has today received information that the certification process under the new Medical Device Regulation (MDR 2017/745) has been slightly delayed due to resource issues at the notified body. - [SciBase announces a Management team change](https://scibase.com/uk/scibase-announces-a-management-team-change-3/) - SciBase's head of product development, David Melin, has resigned from his position and has accepted a role at another company. The company is reviewing options for the role going forward. "I would like to take the opportunity to thank David for his exceptional work at SciBase, and especially his work with our Nevisense hardware platforms. David has managed a very well-functioning development team, and I wish him all the best in his future role", says Simon Grant CEO SciBase. For more information, please contact: Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: simon.grant@scibase.com Certified Advisor (CA): Avanza Tel: +46 8 409 421 20 Email: ca@avanza.se The information was submitted, through the agency of the contact person set out above, for publication at the time stated by SciBase's news distributor Cision upon publication of this press release. About SciBase and NevisenseSciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com. - [Notice to attend the annual general meeting in SciBase Holding AB (publ)](https://scibase.com/uk/notice-to-attend-the-annual-general-meeting-in-scibase-holding-ab-publ/) - The shareholders in SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby given notice to attend the annual general meeting at 15:00 p.m. on Thursday 13 June 2024 at Setterwalls Advokatbyrå's offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences at 14:45 p.m. The board of directors has decided, pursuant to Chapter 7, Section 4a of the Swedish Companies Act and the Company's articles of association, to apply the possibility of postal voting in conjunction with the general meeting (see "Postal voting" below for more information). - [Changes in SciBase's financial calendar for 2021](https://scibase.com/uk/changes-in-scibases-financial-calendar-for-2021/) - SciBase Holding AB (”SciBase” or the “Company”) has updated the Company’s financial calendar for 2021. - [SciBase nominating committee proposes the election of Dr Matt Leavitt as a new Board member](https://scibase.com/uk/scibase-nominating-committee-proposes-the-election-of-dr-matt-leavitt-as-a-new-board-member/) - STOCKHOLM, SWEDEN, — April 27, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the Nominating Committee proposes the election of Dr. Matt Leavitt as a new Board member to the 2021 Annual General Meeting. - [SciBase's US Partner study shows COVID-19 delaying skin cancer diagnosis](https://scibase.com/scibases-us-partner-study-shows-covid-19-delaying-skin-cancer-diagnosis-3/) - A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases remain. Rates of skin cancer detection in the study were down by 43-51%. These delays in initial diagnosis and treatment may lead to skin cancers presenting at more advanced stages, with potential increased morbidity and worse melanoma survival outcomes. The study was based on data collected by the Advanced Dermatology and Cosmetic Surgery (ADCS) group of practices in the US. ADCS is a key partner for SciBase in the US, though SciBase was not directly involved in the study. "This study shows that COVID-19 has had a significant negative effect on the rates of skin cancer diagnosis, primarily due to a reluctance from patients to visit clinics. This effect has been seen in Europe as well. We expect an increased focus on skin cancer and diagnosis once effects of the pandemic have subsided, and this represents a likely increase in demand for products such as ours", says Simon Grant, CEO of SciBase. The article can be accessed through the following link: https://www.jaad.org/article/S0190-9622%2821%2900082-7/fulltext For more information please contact:Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: simon.grant@scibase.com Certified Advisor:Avanza Tel: +46 8 409 421 20 Email: ca@avanza.se About SciBase and NevisenseSciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com. - [Nature article presents impact and importance of epithelial barrier damage on a range of common diseases.](https://scibase.com/uk/nature-article-presents-impact-and-importance-of-epithelial-barrier-damage-on-a-range-of-common-diseases/) - STOCKHOLM, SWEDEN, - April 15, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a groundbreaking article presenting the "epithelial barrier hypothesis" in Nature Reviews Immunology. The article was written by Professor Cezmi Akdis at the Swiss institute of Allergy and Asthma Research (SIAF). Prof. Akdis is the key research collaborator in SciBase's product development for skin barrier assessment. The article presents the background for the steep increase in allergic diseases over the last decades, and how this increase is connected to industrialization and modern lifestyle. - [Advanced Dermatology and Cosmetic Surgery and SciBase team up to raise awareness of skin cancer](https://scibase.com/advanced-dermatology-and-cosmetic-surgery-and-scibase-team-up-to-raise-awareness-of-skin-cancer/) - STOCKHOLM, SWEDEN, — May 3, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today, on "Melanoma Monday", their joint efforts with Advanced Dermatology and Cosmetic Surgery ("ADCS") - the premier dermatology network in the US with over 150 practices - to raise awareness of melanoma and educate around the dangers of the fastest growing and most deadly form of skin cancer to commemorate Skin Cancer Awareness Month. - [SciBase submits first reimbursement application to CMS in Florida](https://scibase.com/uk/scibase-submits-first-reimbursement-application-to-cms-in-florida/) - STOCKHOLM, SWEDEN, — May 4, 2021 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that an application for Medicare coverage of the Nevisense procedure has been submitted in Florida. - [SciBase receives important European MDR certification](https://scibase.com/uk/scibase-receives-important-european-mdr-certification/) - STOCKHOLM, SWEDEN, — May 10, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has been granted certification under the new Medical Device Regulation (MDR). - [SciBase launches Non-melanoma Skin cancer indication for Nevisense](https://scibase.com/uk/scibase-launches-non-melanoma-skin-cancer-indication-for-nevisense/) - STOCKHOLM, SWEDEN, — May 11, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process. - [Annual general meeting has been held in SciBase Holding AB (publ)](https://scibase.com/uk/annual-general-meeting-has-been-held-in-scibase-holding-ab-publ-2/) - Today, the annual general meeting of 2021 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting. - [SciBase raises SEK 71.2 million through two directed issues](https://scibase.com/uk/scibase-raises-sek-71-2-million-through-two-directed-issues/) - The Board of Directors of SciBase Holding AB (publ.) (“SciBase” or the “Company”) has, with support of the authorization granted by the annual general meeting on 18 May 2021 decided on a directed issue of 13,456,021 shares to a number of Swedish and international investors, including Van Herk Investments B.V. and ÖstVäst Capital Management. Furthermore, the Board of Directors has, conditioned by the approval at the extra general meeting, decided on a directed issue of 239,000 shares to the newly elected Board of Director Dr. Matt Leavitt. Notice of the extraordinary general meeting for approval of the share issue to Dr. Matt Leavitt will be announced separately. - [SciBase presents at Redeye Growth Day 2021](https://scibase.com/scibase-presents-at-redeye-growth-day-2021/) - SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will, on June 2 at 8.50 am, present the latest developments in SciBase at the Redeye Growth Day 2021. The presentation will be broadcasted live and can be followed at https://www.redeye.se/events/808637/redeye-growth-day-2021 where it also will be available afterwards, and in parallel it will be made available at the Company’s page on Redeye.se https://www.redeye.se/company/scibase-holding - [Bulletin from extraordinary general meeting of SciBase Holding AB (publ) on 16 June 2021](https://scibase.com/uk/bulletin-from-extraordinary-general-meeting-of-scibase-holding-ab-publ-on-16-june-2021/) - The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on 16 June 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows: - [Bulletin from extraordinary general meeting of SciBase Holding AB (publ) on 16 June 2021](https://scibase.com/uk/bulletin-from-extraordinary-general-meeting-of-scibase-holding-ab-publ-on-16-june-2021-2/) - The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on 16 June 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows: - [SciBase announces change of Certified Adviser to Vator Securities](https://scibase.com/uk/scibase-announces-change-of-certified-adviser-to-vator-securities/) - SciBase Holding (publ), Reg. No. 556773-4768 (the ”Company”), hereby announces that the Company has entered into an agreement with Vator Securities AB (”Vator Securities”) regarding the service as a Certified Adviser. Vator Securities will be appointed Certified Adviser (CA) on 28 September 2021. Up until then, Avanza Bank AB will continue to act as Certified Adviser for the Company. - [SciBase nominating committee proposes the election of Dr Jvalini Dwarkasing as a new Board member](https://scibase.com/uk/scibase-nominating-committee-proposes-the-election-of-dr-jvalini-dwarkasing-as-a-new-board-member/) - STOCKHOLM, SWEDEN, — August 19, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the Nominating Committee proposes the election of Dr. Jvalini Dwarkasing as a new Board member at an extraordinary general meeting to be proposed by the Board of Directors of SciBase. - [Bulletin from extraordinary general meeting of SciBase Holding AB (publ) on September 7, 2021](https://scibase.com/uk/bulletin-from-extraordinary-general-meeting-of-scibase-holding-ab-publ-on-september-7-2021/) - The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on September 7, 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows: - [SciBase to present at the Vator Healthcare Innovation Summit on October 7, 2021](https://scibase.com/uk/scibase-to-present-at-the-vator-healthcare-innovation-summit-on-october-7-2021/) - SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will present an update on the latest developments from SciBase at the Vator Healthcare Innovation Summit on October 7th at 10.40 am. The presentation will be followed by a short Q&A. The Summit is a digital investor event with some of the most innovative and fast-growing Companies in healthcare represented. All presentations will be in English. - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2022:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2022/) - Erik Esveld (VanHerk Group) Christer Jönsson (Fouriertransform), Iraj Arastoupour, Tord Lendau (Chairman of the Board). - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2022:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2022-2/) - Erik Esveld (VanHerk Group) Christer Jönsson (Fouriertransform), Iraj Arastoupour, Tord Lendau (Chairman of the Board). - [SciBase to present at the Redeye Life Science day on November 11, 2021](https://scibase.com/scibase-to-present-at-the-redeye-life-science-day-on-november-11-2021/) - SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CFO Michael Colérus will present an update on the latest developments from SciBase at the Redeye Life Science day on November11th at 16.10 pm. The presentation will be followed by a short Q&A. The presentation will be broadcasted live and can be followed at https://www.redeye.se/events/815899/redeye-life-science-day-2021 The presentation will also be available at www.redeye.se and on the Company's website i n Redeye Universe. - [Article on consequences of MDR regulation within Dermatology published in JEADV](https://scibase.com/article-on-consequences-of-mdr-regulation-within-dermatology-published-in-jeadv/) - STOCKHOLM, SWEDEN, - November 29, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today, that an article describing the consequences of the new medical device regulation (MDR) in the EU has been published in the journal "Journal of the European Academy of Dermatology and Venereology" (JEADV). - [Advanced Dermatology, P.C. adds ten new Nevisense installations to its extensive practice network.](https://scibase.com/advanced-dermatology-p-c-adds-ten-new-nevisense-installations-to-its-extensive-practice-network/) - Stockholm, Sweden and New York, US, - December 16, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leader of augmented intelligence-based solutions for skin disorders, announced today that it has received an order of ten additional Nevisense systems and electrodes valued at approximately KUSD 100 from Advanced Dermatology, P.C. ("AdvDermPC") in New York City. - [SciBase submits request for payment rate to NGS](https://scibase.com/uk/scibase-submits-request-for-payment-rate-to-ngs/) - STOCKHOLM, SWEDEN, - December 22, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to "National Government Services" (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states. - [SciBase announces a change in the Management team and new head of Quality and Regulatory Affairs.](https://scibase.com/uk/scibase-announces-a-change-in-the-management-team-and-new-head-of-quality-and-regulatory-affairs/) - SciBase has appointed Alf Laurell as Director of Quality Assurance and Regulatory Affairs and Person for Regulatory Compliance (PRRC) for SciBase. Alf joins SciBase from Elekta in Stockholm. The previous head of Quality and Regulatory and PRRC, Niklas Jakobsson has decided to pursue a new opportunity outside the company and as such leaves the SciBase Management team. - [New Study published showing Nevisense impact on clinician confidence and accuracy](https://scibase.com/new-study-published-showing-nevisense-impact-on-clinician-confidence-and-accuracy/) - STOCKHOLM, SWEDEN, - January 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study supporting the use of Nevisense in diagnosing melanoma has been published in "SKIN - The journal of cutaneous medicine". The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions. - [Year-end report 2021](https://scibase.com/uk/year-end-report-2021/) - 2022-02-23 08:00 January 1 - December 31, 2021 The fourth quarter in figures Net sales amounted to TSEK 3,925 (3,055). The loss after tax amounted to TSEK 13,852 (9,839). The loss per share amounted to SEK 0.20 (0.20). The cash flow from current operations was negative in the amount of TSEK 11,709 (10,290). The gross margin reached 52.8% (49.4%). - [SciBase receives largest electrode order from a single clinic valued at 60k€](https://scibase.com/scibase-receives-largest-electrode-order-from-a-single-clinic-valued-at-60ke/) - STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has received its single largest order to date from a single clinic. The order for nearly 2,000 electrodes was received from an existing customer, a private Dermatology clinic in Germany. The order was valued at around 60k€ and will be delivered in April. The company has seen a significant increase in order volume following the announcement of an 8% increase in electrode prices from April 1. - [SciBase Barrier technology part of major immunodermatology project](https://scibase.com/scibase-barrier-technology-part-of-major-immunodermatology-project/) - STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its inclusion in the launch of a multidisciplinary research consortium focused on six different dermatological disorders. The Next Generation Immunodermatology (NGID) consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings. The consortium has received funding of 11.7m euros to stimulate and support innovative approaches to identify and develop novel diagnostic and therapeutic approaches within dermatology. - [SciBase further strengthens patent portfolio](https://scibase.com/uk/scibase-further-strengthens-patent-portfolio/) - STOCKHOLM, SWEDEN, — March 30, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that its patent application : EP Application No. 18729063.0 has been granted by EPO in Europe. This patent is linked to the new measurement procedure instituted recently with the introduction of Nevisense 3.0. - [SciBase publishes the Annual report for 2021](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2021/) - SciBase hereby announces that the Annual report for 2021 is available at the Company's website www.scibase.com. - [German study shows clinical benefit of Nevisense](https://scibase.com/uk/german-study-shows-clinical-benefit-of-nevisense/) - STOCKHOLM, SWEDEN, - April 29, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published this week in Germany demonstrated the clinical benefits of Nevisense in day-to-day practice. The study titled - "Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies" and authored by Dr Liebich et al was published online in the journal Dermato. - [SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022](https://scibase.com/scibase-to-present-at-the-redeye-medtech-diagnostics-seminar-on-may-11-2022/) - SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will present an update on the latest developments from SciBase at the Redeye Medtech & Diagnostics seminar on May 11th at 10.55 pm. The presentation will be followed by a short Q&A. The presentations are live broadcasted at https://www.redeye.se/events/825143/redeye-theme-medtech-diagnostics . The presentation will also be available at www.redeye.se and on the Company's website i n Redeye Universe. - [Interim Report Q1 2022](https://scibase.com/uk/interim-report-q1-2022/) - January 1 - March 31, 2022 - [Annual general meeting has been held in SciBase Holding AB (publ) 2022](https://scibase.com/uk/annual-general-meeting-has-been-held-in-scibase-holding-ab-publ-2022/) - 2022-05-18 14:15 Today, the annual general meeting of 2022 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the resolutions passed at the annual general meeting. The annual general meeting resolved: to adopt the profit and loss statement and the balance sheet and the group profit and loss - [FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers](https://scibase.com/uk/fda-expert-panel-in-line-with-scibase-position-to-keep-stringent-approval-level-for-all-new-skin-lesion-analyzers/) - STOCKHOLM, SWEDEN, - August 9, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the FDA (US Food and Drug Administration) held a meeting with the Medical Devices Advisory Committee on July 28th and 29th to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2023:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2023/) - Dharminder Chahal (VanHerk Group) Peter Elmvik (Stockholms Elbolag), Iraj Arastoupour, Tord Lendau (Chairman of the Board). - [New article discusses EIS as a potential clinical measure of skin barrier integrity](https://scibase.com/new-article-discusses-eis-as-a-potential-clinical-measure-of-skin-barrier-integrity/) - STOCKHOLM, SWEDEN, - October 27, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal "Molecular Psychiatry", a part of Nature, named "Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions" discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence. - [SciBase announces collaboration to detect skin barrier dysfunction in infants](https://scibase.com/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants/) - November 7, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants. - [US study shows that EIS and Nevisense significantly improves clinicians' diagnostic accuracy](https://scibase.com/uk/study-shows/) - STOCKHOLM, SWEDEN, - May 16, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled - "Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study" and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor, Dermatology Department, et al at Icahn School of Medicine at Mount Sinai, New York, was published online in "SKIN-The Journal of Cutaneous medicine". - [Nevisense detects skin barrier damage in mice caused by household detergents](https://scibase.com/nevisense-detects-skin-barrier-damage-in-mice-caused-by-household-detergents/) - STOCKHOLM, SWEDEN, - September 1, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today scientific results that demonstrate the detrimental effects that common detergents can have on the health of the skin barrier. Top line results were presented recently at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US). The study demonstrates that household laundry detergents disrupt the skin barrier integrity in mice. - [New study shows Nevisense significantly improves US clinician's decision-making beyond dermoscopy](https://scibase.com/new-study-shows-nevisense-significantly-improves-us-clinicians-decision-making-beyond-dermoscopy-2/) - STOCKHOLM, SWEDEN, - October 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research". The study included 231 US Dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%. - [SciBase CEO Simon Grant gives a comment regarding the collaboration with Johnson & Johnson Consumer Health](https://scibase.com/uk/scibase-ceo-simon-grant-gives-a-comment-regarding-the-collaboration-with-johnson-johnson-consumer-health/) - STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced on Monday November 7 that it has initiated a collaboration with Johnson & Johnson Consumer Health Inc. to develop a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants. - [SciBase invitation to a webinar on November 10 at 11:00 CET](https://scibase.com/uk/scibase-invitation-to-a-webinar-on-november-10-at-1100-cet/) - STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 - 12.00. The event will only be digital. - [Nevisense for skin barrier evaluation included in large Australian birth cohort study](https://scibase.com/nevisense-for-skin-barrier-evaluation-included-in-large-australian-birth-cohort-study/) - STOCKHOLM, SWEDEN, - December 15, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included in one of the world's largest cohort studies - The ORIGINS Project, which is a collaboration between Joondalup Health Campus and Telethon Kids Institute. SciBase will supply Nevisense, Nevisense Go and electrodes to follow up to 1,000 of the 10,000 children included in the project. Of key interest is the development and progression of atopic dermatitis and the project is intending to utilise the Nevisense system to assess skin integrity in this context. - [SciBase resolves on a fully guaranteed rights issue of approximately SEK 79.6 million](https://scibase.com/uk/scibase-resolves-on-a-fully-guaranteed-rights-issue-of-approximately-sek-79-6-million/) - The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 79.6 million before transaction costs. - [SciBase publishes prospectus in connection with fully guaranteed rights issue](https://scibase.com/scibase-publishes-prospectus-in-connection-with-fully-guaranteed-rights-issue/) - The board of directors of SciBase Holding AB (publ) ("Scibase" or the "Company") has prepared a prospectus in connection with the issue of shares with preferential rights for the Company's shareholders of approximately SEK 79.6 million (the "Rights Issue") announced by the Company through press release on February 13, 2023. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company's website. - [SciBase publishes the Annual report for 2022](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2022/) - SciBase hereby announces that the Annual report for 2022 is available at the Company's website www.scibase.com. - [Correction of headline in published Interim report January - March 2023](https://scibase.com/uk/correction-of-headline-in-published-interim-report-january-march-2023/) - Headline of previously published Interim report January - March 2023 corrected including the headline in the attached pdf-file - [SciBase announces changes in senior management](https://scibase.com/uk/scibase-announces-changes-in-senior-management/) - STOCKHOLM, SWEDEN, - May 15, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that Simon Grant has resigned from his position as CEO for personal reasons and will be transitioning out of his role over the next six months. Simon Grant will remain available to the Board in a consulting capacity after the end of the planned transition time. - [SciBase announces outcome of rights issue of shares](https://scibase.com/uk/scibase-announces-outcome-of-rights-issue-of-shares/) - The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the fully guaranteed rights issue of shares with preferential rights for SciBase's shareholders (the "Rights Issue") which was resolved upon by the board of directors on 13 February 2023 by virtue of the authorization from the annual general meeting on 18 May 2022. In total, 26,182,918 shares were subscribed for with support of subscription rights, corresponding to approximately 51 percent of the Rights Issue. 12,705,290 shares, corresponding to approximately 25 percent of the Rights Issue, have been allotted to persons who have subscribed for shares without support of subscription rights. Therefore, the issue guarantors are allotted approximately 24 percent of the Rights Issue. SciBase will receive approximately SEK 79.6 million before deduction for transaction costs. - [SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations](https://scibase.com/scibase-and-schweiger-dermatology-group-partner-to-advance-skin-cancer-detection-in-select-new-jersey-locations/) - STOCKHOLM, SWEDEN, - March 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Schweiger Dermatology group ("SDG") to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut. The agreement will provide Schweiger Dermatology Group's Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care. - [SciBase receives increased US Medicare fee schedules for the Nevisense melanoma test](https://scibase.com/scibase-receives-increased-us-medicare-fee-schedules-for-the-nevisense-melanoma-test-2/) - STOCKHOLM, SWEDEN, - April 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) have published updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1st January 2023 and are available on the MAC's respective webpages. - [SciBase receives increased US Medicare fee schedules for the Nevisense melanoma test](https://scibase.com/scibase-receives-increased-us-medicare-fee-schedules-for-the-nevisense-melanoma-test/) - STOCKHOLM, SWEDEN, - April 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) have published updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1st January 2023 and are available on the MAC's respective webpages. - [Clarification regarding announcement of senior management changes in SciBase](https://scibase.com/uk/clarification-regarding-announcement-of-senior-management-changes-in-scibase/) - STOCKHOLM, SWEDEN, - May 15, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby clarifies the May 15th announcement that Simon Grant will leave his position as CEO for personal reasons. Simon will transition out of his role over the next six months but will remain formally as CEO during this time. Simon Grant will also remain available to the Board in a consulting capacity after the end of the planned transition time. - [Letter from the Chairman of the Board](https://scibase.com/uk/letter-from-the-chairman-of-the-board/) - Midsummer approaches and, as you know, Simon resigned a few weeks ago so we would like to give you a quick update on the recent progress at SciBase. - [SciBase appoints Pia Renaudin as Chief Executive Officer](https://scibase.com/uk/scibase-appoints-pia-renaudin-as-chief-executive-officer/) - STOCKHOLM, SWEDEN, - August 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that the Board has appointed Pia Renaudin as the Company's Chief Executive Officer (CEO). - [SciBase strengthens US team with experienced Dermatology executive](https://scibase.com/scibase-strengthens-us-team-with-experienced-dermatology-executive/) - STOCKHOLM, SWEDEN, - September 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby announces that Dan Walker has been appointed as VP US Commercial Operations. - [SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas](https://scibase.com/scibase-initiates-pilot-with-bare-dermatology-to-advance-skin-cancer-detection-in-texas/) - STOCKHOLM, SWEDEN, - September 25, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas. Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists. The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care. - [Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis](https://scibase.com/nevisense-detects-skin-barrier-dysfunction-in-children-with-atopic-dermatitis/) - STOCKHOLM, SWEDEN, - September 28 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the clinical results from a study performed together with the University Children's Hospital Zürich. The study demonstrates the ability of Nevisense to distinguish children with and without Atopic Dermatitis (AD). - [Nevisense detects skin barrier damage from skin models in research](https://scibase.com/nevisense-detects-skin-barrier-damage-from-skin-models-in-research/) - STOCKHOLM, SWEDEN, - September 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device. - [Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2024](https://scibase.com/uk/nomination-committee-appointed-for-scibase-holdings-annual-general-meeting-in-2024/) - The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2024: - [SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California](https://scibase.com/scibase-and-skin-and-cancer-institute-partner-to-advance-ai-driven-skin-cancer-detection-in-california/) - STOCKHOLM, SWEDEN, - November 16, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more than 50 offices across a three-state network comprised of California, Arizona and Nevada, they are one of the largest dermatology groups in the country. The collaboration will provide the Skin and Cancer Institute's group with Nevisense, the only AI-driven FDA approved test for early melanoma detection at point-of-care. - [Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection](https://scibase.com/skin-cancer-and-reconstructive-surgery-center-of-california-adopts-ai-driven-nevisense-for-early-skin-cancer-detection/) - STOCKHOLM, SWEDEN, - December 04, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center ("SCARS Center") in California. This partnership will help further introduce Nevisense to a broader US market. The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks. - [SciBase capital markets day 2024 - save the date](https://scibase.com/uk/scibase-capital-markets-day-2024-save-the-date/) - STOCKHOLM, SWEDEN, - December 28, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024. - [Welcome to SciBase Capital Markets Day 2024](https://scibase.com/uk/welcome-to-scibase-capital-markets-day-2024/) - STOCKHOLM, SWEDEN, - January 25, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024. - [Reminder: Welcome to SciBase Capital Markets Day 2024](https://scibase.com/reminder-welcome-to-scibase-capital-markets-day-2024/) - STOCKHOLM, SWEDEN, - January 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day on January 25, 2024. - [SciBase initiates collaboration with Inderes for commissioned research](https://scibase.com/scibase-initiates-collaboration-with-inderes-for-commissioned-research/) - STOCKHOLM, SWEDEN, - January 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology initiates cooperation with Inderes (www.inderes.se) for ongoing services related to commissioned research. This collaboration aims at providing high-quality equity research on SciBase Holding AB stock. - [New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL](https://scibase.com/uk/new-study-shows-nevisense-evaluates-skin-barrier-function-with-less-sensitivity-to-lifestyle-factors-than-tewl/) - STOCKHOLM, SWEDEN, - February 16, 2024 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the first direct comparison between electrical impedance spectroscopy (EIS) using Nevisense and trans-epidermal water loss (TEWL). The study demonstrates Nevisense as a more robust technique to assess skin barrier function than the commonly accepted TEWL measurement technique. - [Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami](https://scibase.com/keynote-speakers-presented-nevisense-at-the-2024-winter-clinical-dermatology-conference-in-miami/) - STOCKHOLM, SWEDEN, - February 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami. The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology. This prestigious CME course attracts over 400 dermatologists from the US and is considered to be one of the leading educational events for dermatology professionals. - [SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform](https://scibase.com/uk/scibase-partners-with-skinobs-to-offer-nevisense-on-global-cosmetic-testing-platform/) - STOCKHOLM, SWEDEN, - February 28, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Skinobs, a leading global platform connecting researchers with the tools they need for their cosmetic and medical research. Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform. - [Notice to extraordinary general meeting in Scibase Holding AB (publ)](https://scibase.com/uk/notice-to-extraordinary-general-meeting-in-scibase-holding-ab-publ/) - Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held on 13 May 2024 at 09.00 CEST at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 08.30 CEST. - [Today is the first day of the subscription period in SciBase rights issue](https://scibase.com/uk/today-is-the-first-day-of-the-subscription-period-in-scibase-rights-issue/) - Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million commences (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023. - [SciBase will present at the Redeye Medtech Event on April 24[th]](https://scibase.com/scibase-will-present-at-the-redeye-medtech-event-on-april-24th/) - STOCKHOLM, SWEDEN, - April 23, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders will participate at the Redeye Medtech event. - [SciBase resolves on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million](https://scibase.com/uk/scibase-resolves-on-a-directed-issued-of-approximately-sek-33-million-and-a-rights-issue-of-approximately-sek-15-million/) - The Board of Directors SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved on a capital raise totaling approximately SEK 48 million (the "Capital Raising"). The Capital Raising consists of both a new issue of so called units, consisting of shares and warrants of series TO 2, with deviation from the existing shareholders' preferential rights, of approximately SEK 33 million to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Ulti AB , Van Herk Investments B.V., Morningside Group AB, Matt Leavitt, Viktor Drvota, Theodor Invest AB and Eric Terhaerdt (the "Directed Issue"), and a new rights issue of so called units, consisting of shares and warrants of series TO 2, with preferential rights for the Company's existing shareholders of approximately SEK 15 million (the "Rights Issue"). One unit in the Rights Issue and the Directed Issue, respectively, consist of one (1) new share and five (5) warrants of series TO 2 in the Company. The Directed Issue is subject to approval by an Extraordinary General Meeting (the "EGM") intended to be held on 13 May 2024. The Company has in connection with the Rights Issue received subscription commitments totaling approximately SEK 2.5 million, corresponding to approximately 16 percent of the Rights Issue. - [SciBase publishes prospectus in connection with upcoming rights issue](https://scibase.com/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue/) - On 5 April 2024, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units, consisting of new shares and warrants of series TO 2, of approximately SEK 15 million (the "Rights Issue). Today, SciBase announces that the prospectus relating to the Rights Issue (the "Prospectus") has been approved by the Swedish Financial Supervisory Authority (the "SFSA") and has been made available on the Company's webpage, https://investors.scibase.se/en/share/prospectus-regarding-shares, together with other information related to the Rights Issue. The Prospectus will also be made available on Vator Securities' webpage, www.vatorsecurities.se , and at the SFAS's webpage, www.fi.se. - [SciBase Partners with Al Shirawi Healthcare solutions to Offer Nevisense in UAE](https://scibase.com/uk/scibase-partners-with-al-shirawi-healthcare-solutions-to-offer-nevisense-in-uae/) - STOCKHOLM, SWEDEN, - April 24, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies across multiple specialities of aesthetics dermatology, orthopedics and medical consumables In Dubai. Through this partnership, Nevisense will now be available for patients in the United Arab Emirates (UAE). - [SciBase supports clinicians during US Skin Cancer Awareness Month](https://scibase.com/scibase-supports-clinicians-during-us-skin-cancer-awareness-month/) - STOCKHOLM, SWEDEN, - May 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in skin cancer detection and prevention, and prediction in dermatology, further deepens their commitment to patients and dermatologists during US Skin Cancer Awareness Month by highlighting the importance of early detection and prevention of skin cancer and helping improve outcomes for clinicians and patients. - [Last day of trading in unit rights in SciBase rights issue](https://scibase.com/uk/last-day-of-trading-in-unit-rights-in-scibase-rights-issue/) - Today, 2 May 2024, is the last day of trading in unit rights in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023. - [SciBase announces outcome in rights issue of units](https://scibase.com/uk/scibase-announces-outcome-in-rights-issue-of-units/) - The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome in the rights issue of so called units, consisting of shares and warrants of series TO 2 ("Units"), with preferential rights for the Company's existing shareholders of approximately SEK 15 million which was resolved upon by the Board of Directors on 5 April 2024 by virtue of the authorization from the annual general meeting on 17 May 2023 (the "Rights Issue"). The subscription price in the Rights Issue was SEK 0.42 per Unit, corresponding to SEK 0.42 per share. The warrants of series TO 2 are issued free of charge. The subscription period in the Rights Issue ended on 7 May 2024. 13,264,074 Units were subscribed for with support of unit rights, corresponding to approximately 37 percent of the Rights Issue. 8,493,194 Units, corresponding to approximately 24 percent of the Rights Issue, have been allotted to persons who have subscribed for Units without support of unit rights. In total, 21,757,268 Units were subscribed for in the Rights Issue, corresponding to approximately 61 percent of the Rights Issue. Through the Rights Issue, the Company will initially receive proceeds of approximately SEK 9 million before deduction of transaction costs. If all warrants of series TO 2 issued in the Rights Issue are exercised for subscription of shares the Company will receive additional proceeds of approximately SEK 46 million before deduction of transaction costs. - [Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)](https://scibase.com/uk/bulletin-from-the-extraordinary-general-meeting-in-scibase-holding-ab-publ/) - Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to attend the meeting (which is available on the Company's website (www.scibase.com)): - [SciBase publishes the Annual report for 2023](https://scibase.com/uk/scibase-publishes-the-annual-report-for-2023/) - SciBase hereby announces that the Annual report for 2023 is available at the Company's website www.scibase.com. - [SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing](https://scibase.com/uk/scibase-announces-the-launch-of-ebarrier-score-the-first-ai-driven-skin-barrier-assessment-tool-for-research-and-cosmetic-testing/) - STOCKHOLM, SWEDEN, - May 29, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce the launch of the eBarrier Score for Nevisense, the first-ever AI skin barrier assessment tool built for use in research and cosmetic testing. The eBarrier Score was announced today at the Cosmetotest cosmetic testing symposium in Lyon, France. - [SciBase announces outcome in the directed issue of units](https://scibase.com/uk/scibase-announces-outcome-in-the-directed-issue-of-units/) - On 5 April 2024 SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the general meeting, on directed issues of a total of 77,891,769 units consisting of shares and warrants of series TO 2, with deviation from the shareholders preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general meeting on 13 May 2024 resolved to approve the Directed Issue. All units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of all units in the Directed Issue. - [New German study shows Nevisense significantly improves dermatologists clinical decisions](https://scibase.com/new-german-study-shows-nevisense-significantly-improves-dermatologists-clinical-decisions/) - STOCKHOLM, SWEDEN, - May 22, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new clinical study has been published presenting the improvement that the Nevisense provides over visual and dermoscopic evaluation when clinical evaluations were done by German dermatologists. The article named "Utilizing Data from Electrical Impedance Spectroscopy Significantly Improves the Decision to Biopsy Pigmented Skin Lesions Beyond Clinical Evaluation and Dermoscopy" has been published in the journal "SKIN - The journal of cutaneous medicine". The study included 151 German Dermatologists making a total of 22.197 clinical biopsy decisions. Nevisense was able to improve the rate of correct biopsy choice even after dermoscopic evaluation. While dermoscopy worsened diagnostic accuracy for benign lesions, Nevisense results were able to significantly improve decision making for these lesions as well. This study demonstrates the clinical utility of Nevisense technology for improving melanoma diagnosis. - [SciBase receives first order in Austria](https://scibase.com/scibase-receives-first-order-in-austria/) - STOCKHOLM, SWEDEN, - May 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce that it has received the first order for a Nevisense system with electrodes in Austria. - [Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising](https://scibase.com/uk/today-is-the-first-day-of-trading-in-the-new-shares-and-warrants-of-series-to-2-issued-in-connection-with-the-completed-capital-raising/) - Today, 31 May 2024, trading in the new shares and warrants of series TO 2 begins, which were issued by SciBase Holding AB (publ) ("SciBase" or the "Company") in connection with the capital raising announced by the Company on 5 April 2024, consisting of a rights issue of units of up to approximately SEK 15 million (the "Rights Issue") and a directed issue of units of approximately SEK 33 million (the "Directed Issue" and together with the Rights Issue the "Capital Raising"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023, and the Directed Issue was resolved by the Board of Directors on 5 April 2024, conditional on the subsequent approval by the general meeting. The extraordinary general meeting in the Company on 13 May 2024 resolved to approve the Board of Directors resolution to carry out the Directed Issue. - [The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2021:](https://scibase.com/uk/the-following-people-have-been-appointed-as-members-of-scibase-holdings-nominating-committee-for-the-annual-general-meeting-in-2021/) - Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles ... ## Pages - [Startpage](https://scibase.com/uk/) - Leading developer of augmented intelligence-based solutions for skin disorders. - [Creating a new standard in eczema care](https://scibase.com/uk/creating-a-new-standard-in-eczema-care/) - [Skin Barrier Assessment](https://scibase.com/uk/skin-barrier-assessment/) - [MELANOMA](https://scibase.com/uk/the-nevisense-product/) - [Founder of SciBase](https://scibase.com/founder-of-scibase/) - [ADVANCING EARLY MELANOMA DETECTION IN CLINICAL PRACTICE](https://scibase.com/advancing-early-melanoma-detection-in-clinical-practice/) - [AVAILABLE MARKETS](https://scibase.com/uk/available-markets/) - [CAREERS](https://scibase.com/uk/careers/) - [WHY NEVISENSE?](https://scibase.com/uk/why-nevisense/) - [WE ARE SCIBASE](https://scibase.com/uk/we-are-scibase/) - [Vator Securities Life Science Summit](https://scibase.com/uk/vator-securities-life-science-summit/) - [Webinar with SciBase CEO Simon Grant and Professor Cezmi A. Akdis.](https://scibase.com/uk/webinar-with-scibase-ceo-simon-grant-and-professor-cezmi-a-akdis/) - [USER EXPERIENCE DR. KURZEN](https://scibase.com/user-experience/) - [THE EIS TECHNOLOGY](https://scibase.com/uk/the-eis-technology/) - [USER EXPERIENCE DR. GAHLEN](https://scibase.com/user-experience-dr-gahlen/) - [USER EXPERIENCE DR. KURZEN- QUOTE](https://scibase.com/user-experience-quote/) - [USER EXPERIENCE DR. GAHLEN-QUOTE](https://scibase.com/user-experience-dr-gahlen-quote/) - [THE NEVISENSE PLATFORM](https://scibase.com/uk/the-nevisense-platform/) - [PRESS RELEASES](https://scibase.com/uk/press-releases-scibase/) - [PUBLIKATIONEN](https://scibase.com/uk/publications/) - Wissenschaftliche Publikationen zur SciBase-Technologie: 1. EIS in Bezug auf Hautkrebs Comparing Improvements in Biopsy Decision Making with Electrical Impedance Spectroscopy Between US and German Dermatologists, D Zakria, N Brownstone, M Shah, MD3, J Burshtein, L DeBusk, A Rosenberg, D Rigel, SKIN Jan 2025, Vol 9 Issue 1, DOI https://doi.org/10.25251/skin.9.1.5 Advances in Technology for Melanoma Diagnosis - [SKIN CANCER INFORMATION](https://scibase.com/uk/skin-cancer-information/) - [PATIENT ORGANIZATIONS](https://scibase.com/uk/patient-organizations/) - [QUIZ](https://scibase.com/uk/quiz/) - [SELF EXAMINATION](https://scibase.com/uk/self-examination/) - [OUR ELECTRODES](https://scibase.com/our-electrodes/) - [QUOTE DR. HAUSCHILD](https://scibase.com/uk/quote/) - [press-rss](https://scibase.com/uk/press-rss/) - [Privacy and Cookie policy](https://scibase.com/uk/privacy-cookie-policy/) - [Patient Labeling](https://scibase.com/uk/patient-labeling/) - [USER EXPERIENCES](https://scibase.com/scibase-increased-diagnostic-accuracy-in-the-detection-of-malignant-melanoma/user-experience-dr-goldenberg/) - [Skin Barrier research with EIS](https://scibase.com/uk/barrier-research-with-eis/) - [SciBase appoints Pia Renaudin as Chief Executive Officer](https://scibase.com/uk/scibase-appoints-pia-renaudin-as-chief-executive-officer/) - [SciBase Capital Markets Day](https://scibase.com/uk/scibase-capital-markets-day/) - [HOW TO MEASURE](https://scibase.com/uk/how-to-measure/) - [MULTIPLE READERS MULTIPLE CASE](https://scibase.com/multiple-readers-multiple-case/) - [FIND CLINICS](https://scibase.com/uk/find-clinics/) - [FINANCIAL REPORTS](https://scibase.com/uk/financial-reports/) - [NEVISENSE 3.0](https://scibase.com/uk/nevisense3/) - Nevisense - [INDICATION FOR USE](https://scibase.com/indication-for-use/) - [Investor Linkbox](https://scibase.com/uk/investor-linkbox/) - [nevisense iframe](https://scibase.com/uk/nevisense-iframe/) - Search Options 5 km 10 km 25 km 50 km 100 km 200 km 500 km Select category - [Nevisense indication for Keratinocyte cancer](https://scibase.com/uk/nevisense-indication-for-keratinocyte-cancer/) - [Evaluation of Electrical Impedance as a tool to assess skin barrier dysfunction induced by tape stripping](https://scibase.com/uk/evaluation-of-electrical-impedance-as-a-tool-to-assess-skin-barrier-dysfunction-induced-by-tape-stripping/) - [nevisense iframe berlin](https://scibase.com/uk/nevisense-iframe-berlin/) - Search Options 5 km 10 km 25 km 50 km 100 km 200 km 500 km Select category - [Management Germany](https://scibase.com/uk/management-germany/) - [Letter from the Board](https://scibase.com/uk/letter-from-the-board/) - [Nevisense detects skin barrier dysfunction](https://scibase.com/nevisense-detects-skin-barrier-dysfunction-in-children-with-atopic-dermatitis/) - [Introducing Pia Renaudin](https://scibase.com/uk/introducing-pia-renaudin/) - [CLINICAL BENEFITS](https://scibase.com/uk/clinical-benefits/) - [CLINICAL STUDIES](https://scibase.com/uk/clinical-studies/) - [CEO-LETTERS](https://scibase.com/uk/ceo-letters/) - [CONTACT](https://scibase.com/uk/contact/) - [CEO-LETTER 3](https://scibase.com/uk/ceo-letter-3/) - [CEO-LETTER-1](https://scibase.com/uk/ceo-letter-1/) - [CEO-LETTER 2](https://scibase.com/uk/ceo-letter-2/) - [CEO-LETTER 4](https://scibase.com/uk/ceo-letter-4/) - [CEO LETTER 9](https://scibase.com/uk/ceo-letter-9/) - [ABOUT SCIBASE](https://scibase.com/uk/about-scibase/) - [CEO LETTER 5](https://scibase.com/uk/ceo-letter-5/) - [CEO LETTER 6](https://scibase.com/uk/ceo-letter-6/) - [CEO LETTER 7](https://scibase.com/uk/ceo-letter-7/) - [CEO LETTER 8](https://scibase.com/uk/ceo-letter-8/) - [CEO LETTER 10](https://scibase.com/uk/ceo-letter-10/) - [CEO LETTER 11](https://scibase.com/uk/ceo-letter-11/) - ["We continue our momentum across all markets"](https://scibase.com/uk/we-continue-our-momentum-across-all-markets/) - ["SciBase has advanced its positions significantly and laid the foundation for continued growth"](https://scibase.com/uk/scibase-has-advanced-its-positions-significantly-and-laid-the-foundation-for-continued-growth/) ## Events - [AAD Annual Meeting](https://scibase.com/uk/event/aad-annual-meeting-3/) - The 2027 AAD Annual Meeting is scheduled to take place March 19-23, 2027, in San Francisco, California. - [PDFs Årsmöte](https://scibase.com/uk/event/pdfs-arsmote/) - SciBase kommer att delta under Privatpraktiserande Dermatologers Årsmöte i Mölndal. 28-29 augusti 2026 Föreningen, som är en organisation för läkare verksamma inom privat dermatologisk verksamhet, erbjuder ett program med föreläsningar och diskussioner om praktisk dermatologi och nytt inom forskningen. Det är ett forum för att lyfta och driva frågor av betydelse för Sveriges privatpraktiserande dermatologer. - [Derm-Alpin](https://scibase.com/event/derm-alpin/) - [SGDV 2026](https://scibase.com/uk/event/sgdv-2026/) - [OEADF Jahrestagung](https://scibase.com/uk/event/oeadf-jahrestagung/) - [Advancing Early Melanoma Detection in Clinical Practice](https://scibase.com/event/nevisense-early-detection-that-matters-webinar-with-dr-hauschild/) - ADVANCING EARLY MELANOMA DETECTION IN CLINICAL PRACTICE Join us for a scientific webinar with Prof. Dr. Axel Hauschild on early detection in melanoma and skin cancer. The webinar will examine how advanced diagnostic tools, such as Nevisense, can support clinicians in early detection by integrating new strategies into their everyday clinical practice. Date & Time: - [22nd EADO CONGRESS](https://scibase.com/uk/event/22nd-eado-congress/) - [Suppliers Day](https://scibase.com/uk/event/suppliers-day/) - [Cosmetotest](https://scibase.com/uk/event/cosmetotest/) - SciBase will take part at the annual cosmetic conference Cosmetotest! Cosmetotest is the International Symposium on Preclinical and Clinical Testing in dermocosmetics Lyon & Hybrid 18-19 March 2026 To learn more about Nevisense for cosmetic testing, or to schedule a meeting, contact jonas.fredriksson@scibase.com - [EACCI Annual Congress](https://scibase.com/uk/event/eacci-annual-congress/) - EACCI Annual Congress will take place at the ICC in Istanbul, Contact us to learn more or to schedule a meeting! info@scibase.com - [FOBI 2026](https://scibase.com/uk/event/fobi-2026/) - FOBI 2026 -Continuing Education Week for Practical Dermatology and Venereology is organized by INTERPLAN Fortbildungswoche GmbH and will be held from Jul 06 - 10, 2026 at Clinic for Dermatology and Allergology - LMU Munich, Munich, Bavaria, Germany. - [AAD annual Congress](https://scibase.com/uk/event/aad-annual-congress/) - The 2026 AAD Annual Meeting is scheduled to take place March 27–31, 2026, in Denver, Colorado, bringing you the latest developments in the field and the opportunities to connect with the best in dermatology. SciBase will be on site, showcaseing Nevisense for melanoma detection and skin barrier assessment. Contact our teams to learn more or - [Derm Frankenthal](https://scibase.com/event/derm-frankenthal/) - SciBase is happy to take part in the annual Derm Frankenthal meeting. Contact our team to learn more or to schedule a meeting! info@nevisense.de - [SCC79 Annual Meeting](https://scibase.com/uk/event/scc79-annual-meeting/) - Join us December 16-17, 2025, in New York City! LOCATION: Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York, NY 10019 The 79th Annual Scientific Meeting & Showcase is the must-attend event for anyone involved in the cosmetic industry. Join us for 2 full days of cutting-edge insights at - [The 10th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine](https://scibase.com/event/the-10th-international-congress-of-medical-excellence-in-dermatology-aesthetic-medicine/) - The 10th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine | 25-27 September 2025 | MEIDAM 2025 | MEIDAM - House of Dermatology https://www.meidamcongress.com/ - [ÖGDV 2025](https://scibase.com/uk/event/ogdv-2025/) - [TAMC 2025](https://scibase.com/uk/event/tamc-2025/) - [DermaPraxis Berlin](https://scibase.com/event/dermapraxis-berlin-2/) - [Haut und Harz RevivalVIII – Jahrestagung des LV Sachsen-Anhalt im BVDD](https://scibase.com/event/haut-und-harz-revivalviii-jahrestagung-des-lv-sachsen-anhalt-im-bvdd/) - [5. Chemnitzer Dermakonzil](https://scibase.com/event/5-chemnitzer-dermakonzil/) - [6. Jenaer Dermakonzil](https://scibase.com/event/6-jenaer-dermakonzil/) - [Webinar - What's trending in testing from NYSCC Supplier's Day](https://scibase.com/uk/event/webinar-whats-trending-in-testing-from-nyscc-suppliers-day/) - Follow the link for more info and registration: https://us06web.zoom.us/webinar/register/WN_3jiq_QdXQz23yjiHAFh3ug - [DermAlpin](https://scibase.com/event/dermalpin/) - [ADO Jahrestagung](https://scibase.com/uk/event/ado-jahrestagung/) - [SGDV Jahreskongress](https://scibase.com/uk/event/sgdv-jahreskongress/) - SGDV Jahreskongress Sep 3-5, 2025 St. Gallen, CH - [OEADF Vienna](https://scibase.com/uk/event/oeadf-vienna/) - [DDL Frankfurt](https://scibase.com/uk/event/ddl-frankfurt/) - [DDG-Jahrestagung](https://scibase.com/uk/event/ddg-jahrestagung/) - [Corius Internal Congress](https://scibase.com/event/corius-internal-congress/) - [Zertifizierungskurs med. Tumortherapie](https://scibase.com/uk/event/zertifizierungskurs-med-tumortherapie/) - Zertifizierungskurs med. Tumortherapie Berlin Germany 23-25 Feb - [EACCI Congress 2025](https://scibase.com/uk/event/eacci-congress-2025/) - EAACI Congress 2025 SciBase will take part in Breaking boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future 13 - 16 June 2025 Glasgow, Scotland https://eaaci.org/events_congress/eaaci-congress-2025/ - [IFSCC Cannes 2025](https://scibase.com/uk/event/ifscc-cannes/) - SciBase participates as a sponsor at the gongress held in Cannes between the 15th and the 17th of september. https://ifscc2025.com/en/ - [DERM in Frankenthal](https://scibase.com/event/derm-in-frankenthal/) - 23. Tagung DERM 21 - 23 März/ Marsch 2025 im CongressForum in Frankenthal https://www.kongress-derm.de/ - [Cosmetotest 2025](https://scibase.com/uk/event/cosmetotest-2025/) - The International Preclinical and Clinical Testing Symposium will be back in Lyon, in May 14-15, 2025. https://www.cosmetotest.skinobs.com/ - [NYSCC Suppliers' Day](https://scibase.com/uk/event/nyscc-suppliers-day/) - NYSCC Suppliers' Day is one of the largest tradeshows in North America dedicated to product development. It will take place from June 3 to 4, 2025, at the Jacob Javits Convention Center in New York City. SciBase will partner with Skinobs - We are Testing platform to further establish Nevisense as a efficiant researchdevide for - [The 9th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine](https://scibase.com/event/the-9th-international-congress-of-medical-excellende-in-dermatology-aestetic-medicine/) - The 9th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine. Bridgeing gaps, shareing knowledge 15-17 nov Dubai https://www.meidamcongress.com/ (Dubai World Trade Center) - [Tegernseekonferenz - Bad Wiessee, Deutschland](https://scibase.com/event/tegernseekonferenz-bad-wiessee-deutschland/) - 11-13 October Tegernseekonferenz Bad Wiessee, Deutschland - [Diad - Dial](https://scibase.com/uk/event/diad-dial/) - The 6th Meeting of Dual Event Diad - Dial Dial 14 - 16 February 2025 The Ritz-Carlton DIFC, Dubai, United Arab Emirates https://diad-dial.com/ - [2025 AAD Annual Meeting - American Academy of Dermatology](https://scibase.com/event/2025-aad-annual-meeting-american-academy-of-dermatology/) - The 2025 AAD Annual Meeting is scheduled to take place March 7-11 in Orlando, Florida. - [2024 Fall Clinical Dermatology Conference](https://scibase.com/event/2024-fall-clinical-dermatology-conference/) - 2024 Fall Clinical Dermatology Conference October 24 - 27, 2024 | Wynn Las Vegas, NV - [OEADF Vienna Annual Congress](https://scibase.com/uk/event/oeadf-vienna-annual-congress/) - [DERM Alpin Salzburg](https://scibase.com/event/derm-alpin-salzburg/) - [SSDV Annual Congress Basel](https://scibase.com/uk/event/ssdv-annual-congress-basel/) - [WSVD Graz](https://scibase.com/uk/event/wsvd-graz/) - [Cosmetotest 2024](https://scibase.com/uk/event/cosmetotest-2024/) - Cosmetotest - Cosmetic Testing Symposium on 29-30th May 2024 in Lyon COSMETOTEST allows cosmeticians around the world: 1. Listen to academic and applied lectures and interact with participants 2. To meet test partners, exhibitors, CROs or instrumentation manufacturers, 3. To participate in demonstrations of devices made by exhibitors https://www.cosmetotest.skinobs.com/ - [22. Tagung DERM - Frankenthal](https://scibase.com/event/22-tagung-derm-frankenthal/) - [FOBI 2024](https://scibase.com/uk/event/fobi-2024/) - The „FOBI 2024“ offers a comprehensive, well-balanced academic programme, covering the entire spectrum of dermatology and allergology. Hosted in the Klinik für Dermatologie und Allergologie - LMU München, Dermatologische Klinik I - München Klinik & ICM – International Congress Center Munich participants may expect exclusive plenary sessions, a varied course programme, as well as an - [EACCI Congress 2024](https://scibase.com/uk/event/eacci-congress-2024/) - [Winter Clinical Miami](https://scibase.com/uk/event/winter-clinical-miami/) - 2024 Winter Clinical Dermatology Conference - Miami February 16 - 19, 2024 | Fontainebleau Miami Beach, FL https://dermsquared.org/conferences/2024-winter-clinical-miami/overview - [Derm Alpin 2023](https://scibase.com/event/derm-alpin-2023/) - [AAD Annual Meeting 2024](https://scibase.com/uk/event/aad-annual-meeting-2024/) - [18. Tegernsee Konferenz Dermatologie](https://scibase.com/event/18-tegernsee-konferenz-dermatologie/) - UPDATE-ON-DERMATOLOGY 14. Okt. 2022 — 16. Okt. 2022 Hotel "Terrassenhof", Bad Wiessee am Tegernsee, Deutschland Sprachen: Deutsch Wissenschaftliche Leitung: Prof. Dr. med. H.-W. Kaiser, Prof. Dr. med. habil. Uwe Paasch, Dr. med. D. Greiner-Krüger CME-Punkte: 20 - [NAMCP Fall Managed Care Forum](https://scibase.com/uk/event/namcp-fall-managed-care-forum/) - October 19-20 Caesars palace Las Vegas NV https://namcp.org/conferences/fmcf/23/ - [ADO - 33. Deutscher Hautkrebskongress](https://scibase.com/event/ado-33-deutscher-hautkrebskongress/) - ADO-Jahrestagung 33. Deutscher Hautkrebskongress 6-9 September 2023 https://ado-kongress.de/ - [ISAD - 13th Georg Rajka Symposium in Gdansk](https://scibase.com/uk/event/isad-13th-georg-rajka-symposium-in-gdansk/) - SciBase will attend the 13th Georg Rajka Symposium in Gdansk 2023 held by International Society of Atopic Dermatitis. 31 august - 02 September 2023 - [2023 Fall Clinical Dermatology Conference](https://scibase.com/event/2023-fall-clinical-dermatology-conference/) - 2023 Fall Clinical Dermatology Conference October 19 - 22, 2023 | Las Vegas, NV - [E2BRN 2023 CONFERENCE](https://scibase.com/uk/event/e2brn-2023-conference/) - SciBase will attend and support the E2BRN 2023 Conference in Edinburg. https://e2brn.org/2023-e2brn-conference - [EADV Congress 2023 Berlin](https://scibase.com/uk/event/eadv-congress-2023-berlin/) - SciBase will attend the EADV Congress 2023 in Berlin held by the European Academy of Dermatology and Venerology. 11-14 October 2023. https://eadvcongress2023.org/ - [EAACI Hybrid Congress 2023](https://scibase.com/uk/event/eaaci-hybrid-congress-2023/) - Scibase will participate at the EAACI Hybrid Congress 2023 - the largest Allergy Congress worldwide. - [DDG Congress 2023](https://scibase.com/uk/event/ddg-congress-2023/) - DDG Congress 2023 Treffen Sie SciBase auf der 52. Tagung der Deutschen Dermatologischen Gesellschaft (DDG) vom 26. bis 29. April 2023 in Berlin. https://www.derma-tagungen.de/home/release/ddg2023/de-DE - [DERM 2023 Frankenthal](https://scibase.com/event/derm-2023-frankenthal/) - 21. TAGUNG DERM 2023 Auf der bundesweit größten Fachtagung für niedergelassene Dermatologinnen und Dermatologen werden sich etwa 2.000 Teilnehmende in Frankenthal zum wissenschaftlichen Austausch treffen. https://www.kongress-derm.de/ - [ADO Zertifizierungskurs](https://scibase.com/uk/event/ado-zertifizierungskurs/) - Dermato-Onkologie UPDATE 2023 Zertifizierungskurse Feb 2023: https://ado-zertifizierungskurs.de/ - [Onkoderm lectiure](https://scibase.com/event/onkoderm-lectiure/) - 9. SkinCancerAcademy 2023 Diagnostik und Therapie auf höchstem Niveau Diese Veranstaltung ist kostenfrei! https://onkoderm.de/9-skincanceracademy-2023/ - [AAD ANNUAL MEETING 2023](https://scibase.com/uk/event/aad-annual-meeting-2023/) - SciBase will be present at the AAD Annual Meeting 2023! More info: https://www.aad.org/member/meetings-education/am2 - [Winter Clinical - Miami 2023](https://scibase.com/uk/event/winter-clinical-miami-2023/) - Join us February 17-20, 2023 at the InterContinental Miami https://fallclinical.health/ - [2022 Fall Clinical Dermatology Conference](https://scibase.com/event/2022-fall-clinical-dermatology-conference/) - October 20-23, 2022, Wynn Hotel, Las Vegas - [Derm Alpin 2022](https://scibase.com/event/derm-alpin-2022/) - Der internationale Kongress in deutscher Sprache 28.-30. Oktober 2022 - [ADO Kongress 32. Deutscher Hautkrebskongress](https://scibase.com/event/ado-kongress-32-deutscher-hautkrebskongress/) - [AAD 2022](https://scibase.com/uk/event/aad-2022/) - [EAACI 2022](https://scibase.com/uk/event/eaaci-2022/) - [DDL Jahrestagung](https://scibase.com/uk/event/ddl-jahrestagung/) - [16th World Immune Regulation Meeting](https://scibase.com/uk/event/16th-world-immune-regulation-meeting/) - [Dermatologische Praxis](https://scibase.com/event/dermatologische-praxis/) - [Fortbildungswoche](https://scibase.com/uk/event/fortbildungswoche/) - [Dermatologische Praxis 2021](https://scibase.com/event/dermatologische-praxis-2021/) - [Fall Clinical 2021, Live and Virtual](https://scibase.com/uk/event/fall-clinical-2021-live-and-virtual/) - [Winter Clinical (Virtual)](https://scibase.com/uk/event/winter-clinical-virtual/) - [23rd Annual Mount Sinai Winter Symposium](https://scibase.com/uk/event/23rd-annual-mount-sinai-winter-symposium/) - [Dermatologische Praxis 2020 - Online](https://scibase.com/event/dermatologische-praxis-2020-online/) - Deramtologische Praxis 2020 - Online - [DDL 2020](https://scibase.com/uk/event/ddl-2020/) - Der Deutschen Dermatologische Lasergesellschaft 2020 - [Fall Clinical 2020 - Live and Virtual](https://scibase.com/uk/event/fall-clinical-2020/) - Fall Clinical Dermatology Conference 2020, Oct 29 - Nov 1 - [ADO 2020](https://scibase.com/uk/event/ado/) - 30 Deutscher Hautkrebskongress ADO 2020 - [Fortbildungswoche 2020 Digital Congress](https://scibase.com/uk/event/fortbildungswoche-2020-digital-congress/) - Fortbildungswoche 2020 Digital Congress - [AAD 2020 Annual Meeting](https://scibase.com/uk/event/aad-2020-annual-meeting/) - [Fall Clinical Dermatology Conference](https://scibase.com/event/fall-clinical-dermatology-conference-2/) - [EAACI 2019](https://scibase.com/uk/event/eaaci-2019/) - [ADO 2019](https://scibase.com/uk/event/ado-2019/) - [Jahrestagung DDL](https://scibase.com/uk/event/jahrestagung-ddl/) - [AAD Summer Meeting 2019](https://scibase.com/uk/event/aad-summer-meeting-2019/) - [Atlantic Derm Conference 2019](https://scibase.com/event/atlantic-derm-conference-2019/) - [Winter Clinical Dermatology Conference 2019](https://scibase.com/event/winter-clinical-dermatology-conference/) - [Zertifieringskurs med. Tumortherapie 2019, Novotel](https://scibase.com/uk/event/zertifieringskurs-med-tumortherapie-2018-novotel/) - [50. DDG-Tagung, 2019](https://scibase.com/uk/event/50-ddg-tagung-2019/) - [Dermatologische Praxis 2019](https://scibase.com/event/dermatologische-praxis-2018-2/) - [7th ESDO,](https://scibase.com/uk/event/7th-esdo-berlin/) - [AAD 2019](https://scibase.com/uk/event/aad-2019/) - [21st Annual Mount Sinai Winter Symposium](https://scibase.com/uk/event/21st-annual-mount-sinai-winter-symposium/) - [Fall Clinical Dermatology Conference](https://scibase.com/event/fall-clinical-dermatology-conference/) - [27th EADV Congress](https://scibase.com/uk/event/27th-eadv-congress/) - [5th World Congress of Dermoscopy](https://scibase.com/event/5th-world-congress-dermoscopy/) - [26 Deutscher Hautkrebskongress (ADO)](https://scibase.com/event/26-deutscher-hautkrebskongress-ado/) - 26 Deutscher Hautkrebskongress (ADO), 13-15 Sep. 2018, Stuttgart, Germany - [26 Fortbildungswoche (FOBI)](https://scibase.com/uk/event/26-fortbildungswoche-fobi/) - 26 Fortbildungswoche (FOBI), 24-28 Jul 2018, Munich, Germany - [9 Essener Hauttumor Symposium](https://scibase.com/uk/event/9-essener-hauttumor-symposium/) - 9 Essener Hauttumor Symposium, 13 Jan, s2018, Essen Germany - [6th ESDO](https://scibase.com/uk/event/6th-esdo/) - ESDO, 18-20 Jan, 2018, Berlin Germany - [Dermatologische Praxis 2018](https://scibase.com/event/dermatologische-praxis-2018/) - Dermatologische Praxis, Frankenthal, Germany, 9-11 Mar 2018 - [AAD Annual Meeting](https://scibase.com/uk/event/aad-annual-meeting/) - AAD Annual Meeting San Diego, USA February 16-20, 2018 - [Dermatologische Praxis 2017](https://scibase.com/event/dermatologische-praxis-2017/) - Dermatologische Praxis 2017 Frankenthal, Germany, March 17-19, 2017 - [AAD Annual Meeting](https://scibase.com/uk/event/aad-annual-meeting-2/) - AAD Annual Meeting Orlando, Florida, US, March 3-7, 2017 - [49th DDG-Tagung](https://scibase.com/uk/event/49th-ddg-tagung/) - 49th DDG-Tagung Berlin, Germany, April 26-29, 2017 - [Symposium Läkartidningen 2017](https://scibase.com/uk/event/symposium-lakartidningen-2017/) - Symposium Läkartidningen 2017 Stockholm, Sweden, May 10, 2017 - [SSDV Spring 2017](https://scibase.com/uk/event/ssdv-spring-2017/) - SSDV Spring 2017 Jönköping, Sweden 10-12 May, 2017 - [14 EADV Spring Symposium 2017](https://scibase.com/uk/event/14-eadv-spring-symposium-2017/) - 14 EADV Spring Symposium 2017 Brussels, Belgium May 25-28, 2017 - [Småbolagsdagen](https://scibase.com/uk/event/smabolagsdagen/) - Småbolagsdagen Sheraton Hotel, Tegelbacken 6, Stockholm, Sweden June 12, 2017 - [ZDFT](https://scibase.com/uk/event/zdft/) - ZDFT Zürich, Switzerland, June 14-16, 2017 - [BAD](https://scibase.com/uk/event/bad/) - BAD Liverpool, UK, July 4-6, 2017 - [EADV Congress](https://scibase.com/uk/event/eadv-congress/) - EADV Congress Geneva, Switzerland, September 15-17, 2017 - [27 Deutscher Hautkrebskongress](https://scibase.com/event/27-deutscher-hautkrebskongress/) - 27 Deutscher Hautkrebskongress Mainz, Germany, September 21-23, 2017 - [Dermapraxis Berlin](https://scibase.com/event/dermapraxis-berlin/) - Dermapraxis Berlin Berlin, Germany, September 22-24, 2017 - [Fall Clinical Dermatology Conference](https://scibase.com/uk/event/4938/) - Fall Clinical Dermatology Conference Las Vegas, USA October 12-15, 2017 ## People - [Michael Colérus](https://scibase.com/person/michael-colerus/) - [Per Svedenhag](https://scibase.com/person/per-svedenhag/) - [Dr. Emanuel von Kienlin](https://scibase.com/uk/person/dr-emanuel-von-kienlin/) - [Diana Ferro](https://scibase.com/uk/person/diana-ferro/) - [Linn Olsen](https://scibase.com/uk/person/linn-olsen/) - [Pia Renaudin](https://scibase.com/uk/person/pia-renaudin/) - [Angelica Korsfeldt](https://scibase.com/uk/person/angelica-korsfeldt/) - [Robert Molander](https://scibase.com/uk/person/13180/) - [Jesper Høiland](https://scibase.com/uk/person/13183/) - [Leda Beaty](https://scibase.com/uk/person/13577/) - [Anna Eriksrud](https://scibase.com/uk/person/anna-eriksrud/) - [Jennifer Spåren Bengtsson](https://scibase.com/uk/person/jennifer-sparen-bengtsson/) - [Michael Näsström](https://scibase.com/uk/person/michael-nasstrom/) - [Jvalini Dwarkasing](https://scibase.com/uk/person/jvalini-dwarkasing/) - [Stig Ollmar](https://scibase.com/uk/person/stig-ollmar2/) - [Frank Mathé](https://scibase.com/uk/person/frank-mathe/) - [Katja Hardies](https://scibase.com/uk/person/katja-hardies/) - [Ralf Anton](https://scibase.com/uk/person/ralf-anton/) - [Holger Hänßle, PD Dr. Med.](https://scibase.com/uk/person/holger-hansle-pd-dr-med/) - [Josep Malvehy, MD](https://scibase.com/uk/person/josep-malvehy-md/) - [Scott W. Menzies, B. B.S., Ph.D.](https://scibase.com/uk/person/scott-w-menzies-b-b-s-ph-d/) - [David E. Elder, MBChB](https://scibase.com/person/david-e-elder-mbchb/) - [Allan C. Halpern, MD, MSc](https://scibase.com/uk/person/allan-c-halpern-md-msc/) ## Question - [G-M64-4-4](https://scibase.com/uk/question/g-m64-4-4-2/) - [G-F45-7-10](https://scibase.com/uk/question/g-f45-7-10/) - [G-M37-7-8](https://scibase.com/uk/question/g-m37-7-8/) - [G-F36-4-6](https://scibase.com/uk/question/g-f36-4-6/) - [G-F24-3-3](https://scibase.com/uk/question/g-f24-3-3/) - [G-F35-4-7](https://scibase.com/uk/question/g-f35-4-7/) - [G-M70-7-9](https://scibase.com/uk/question/g-m64-4-4/) ## Categories - [Uncategorized](https://scibase.com/category/uncategorized/) ## People - [Management](https://scibase.com/person/management/) - [Board of directors](https://scibase.com/person/board-of-directors/) - [Scientific advisory board](https://scibase.com/person/scientific-advisory-board/) ## Tags - [yes](https://scibase.com/link-box/yes/)